Back to results
US 10,500,213 B2Granted
Compounds that inhibit Mcl-1 protein
AssigneeAmgen Inc.
InventorsSean P. Brown, Kexue Li, Yunxiao Li, Markian M. Stec
Life of this patent
Estimating the term…
Abstract
Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
Claims46
A method of treating cancer, the method comprising:
- administering to a patient in need thereof, a therapeutically effective amount of a compound, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of the stereoisomer thereof, wherein the cancer is a hematologic malignancy and further wherein the compound is selected from:
A method of treating cancer, the method comprising:
- administering to a patient in need thereof, a therapeutically effective amount of a compound, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of the stereoisomer thereof, wherein the cancer is selected from the group consisting of breast cancer, colorectal cancer, skin cancer, melanoma, ovarian cancer, kidney cancer, lung cancer, non-small cell lung cancer, lymphoma, non-Hodgkin's lymphoma, myeloma, multiple myeloma, leukemia, and acute myelogenous leukemia, and further wherein the compound is selected from:
Dependencies are inferred from the claim text.